AstraZeneca admits new shares. AstraZeneca stock costs EUR 139.63 versus EUR 139.63
Published on 10/04/2026 at 18:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
On October 1, 2026, AstraZeneca PLC notified the admission of 9,828 ordinary shares under its employee share schemes through RNS. Separately, AstraZeneca stock was at EUR 139.63 in weekend trading at Lang & Schwarz at 6:00 p.m. CEST on October 4, 2026, unchanged at 0.00 percent versus the EUR 139.63 close at Lang & Schwarz on October 2, 2026.
Weekend trading at Lang & Schwarz
The Lang & Schwarz indication was EUR 139.63 at 6:00 p.m. CEST on October 4, 2026. The bid was EUR 139.10 and the ask was EUR 140.15. The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of AstraZeneca stock.
The last Xetra trading day
The close at Lang & Schwarz on October 2, 2026, was EUR 139.63. The current weekend indication therefore matched that reference price.
Summit investment and clinical collaboration
In a September 28, 2026, announcement, AstraZeneca said it had agreed to invest $2 billion in newly issued equity in Summit Therapeutics to support the development of ivonescimab with antibody-drug conjugates. The companies also agreed to evaluate sonesitatug vedotin with ivonescimab in gastrointestinal cancers. AstraZeneca said the investment would represent rights equivalent to approximately 12.0 percent of Summit’s outstanding common stock, or approximately 10.6 percent on a fully diluted basis, following completion.
Next Xetra session
The next Xetra session is scheduled for October 5, 2026.
